EMED Assembles Top Scientific Advisory Board to Bolster Launch of Breakthrough Infusion Technologies
EMED Technologies, a global leader in drug delivery and innovative infusion therapy devices, today announced the members of its Scientific Advisory Board. The advisers will guide the Company and its leadership team on scientific and strategic matters to deliver patient-centric solutions, with their insights supporting EMED's development of next-generation drug delivery systems for subcutaneous infusion.
The first trio of board members brings deep, complementary expertise spanning clinical neurology, immunology, and healthcare policy:
Jeffrey Allen, M.D. — A renowned neurologist and expert in inflammatory neuropathies, Dr. Allen's clinical and research leadership will help align EMED's pipeline with the evolving needs of patients managing chronic conditions that depend on regular infusion therapy.
Richard L. Wasserman, M.D., Ph.D. — A leading specialist in immunodeficiencies, asthma, and food allergy, Dr. Wasserman has spent decades pioneering subcutaneous immunoglobulin (SCIg) therapy and advancing standards of care for patients with primary immunodeficiency disease.
John C. (Jack) Lewin, M.D. — An expert in healthcare innovation and health policy, Dr. Lewin brings a system-level perspective on access, reimbursement, and the policy environment shaping the future of advanced infusion therapies.
Established in 1991, EMED Technologies designs, manufactures, distributes, and commercializes innovative drug delivery systems for biologics, specialty drugs, and at-home treatments. The advisory board's guidance will reinforce EMED's long-standing collaboration with patients, clinicians, and pharmaceutical partners.
For more information, visit emedtc.com.
About EMED
EMED Technologies is an industry leader in the design, manufacture, and distribution of cutting-edge medical devices. For two decades, EMED Technologies has worked with clinicians, inventors, and medical companies to develop innovative medical products. Today, we are proud that both patients and clinicians can benefit from the fruits of our labor because we offer a wide variety of products and services that improve therapies and enhance clinical benefits. With our dynamic team of professionals, EMED continues to work with clinicians to understand their requirements and improve upon available technologies. In addition to novel technology, EMED is proud to offer licensing agreements for patented and proprietary technologies.
Media contact
For media inquiries, please contact info@emedtc.com.
Original release
The full press release is available on PR Newswire.